New study from Japan below [1].
Not good, & presumably worse for the more efficient Abiraterone than Lupron, say.
First, some terms:
(a) "The α- and ß-diversity of gut microbiota"
alpha diversity pertains to richness/variety
beta diversity is based on a before-after comparison
(b) "microbiota" versus "microbiome"
sometimes used interchangeably but not quite the same: microbiome refers to total genomes, biota to the microorganisms.
(c} "dysbiosis"
what happens in the gut while deprived of androgen.
***
A "24-week observational study investigated the relationship between testosterone levels and changes in gut microbiota in Japanese patients with prostate cancer undergoing ADT. Sequential faecal samples were collected 1 and 2 weeks before ADT, and 1, 4, 12, and 24 weeks after ADT."
"In total, 23 patients completed the study.
"The α- and ß-diversity of gut microbiota decreased significantly at 24 weeks after ADT ...
"Relative abundances of Proteobacteria, Gammaproteobacteria, Pseudomonadales, Pseudomonas, and concentrations of urea, lactate, butyrate, 2-hydroxyisobutyrate and S-adenosylmethionine changed significantly after ADT ...
"There was a significant positive correlation between the abundance of Proteobacteria, a known indicator of dysbiosis, and the concentration of lactate ..."
"The decline in testosterone levels resulted in detrimental changes in gut microbiota. This dysbiosis may contribute to an increase in frailty and an increased risk of adverse outcomes in patients with prostate cancer."
-Patrick
[1] pubmed.ncbi.nlm.nih.gov/354...
Prostate Cancer Prostatic Dis
. 2022 Apr 13. doi: 10.1038/s41391-022-00536-3. Online ahead of print.
Gut environment changes due to androgen deprivation therapy in patients with prostate cancer
Akimasa Kure 1 2 3 , Tomoya Tsukimi 2 4 , Chiharu Ishii 2 4 , Wanping Aw 2 4 , Nozomu Obana 3 , Gaku Nakato 5 , Akiyoshi Hirayama 2 4 , Haruna Kawano 1 , Toshiyuki China 1 , Fumitaka Shimizu 1 , Masayoshi Nagata 1 , Shinji Isotani 1 , Satoru Muto 1 6 , Shigeo Horie 7 8 , Shinji Fukuda 9 10 11 12
Affiliations collapse
Affiliations
1 Department of Urology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
2 Institute for Advanced Biosciences, Keio University, 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata, 997-0052, Japan.
3 Transborder Medical Research Centre, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
4 Systems Biology Programme, Graduate School of Media and Governance, Keio University, 5322 Endo, Fujisawa, Kanagawa, 252-0882, Japan.
5 Kanagawa Institute of Industrial Science and Technology, Life Science & Environment Research Centre (LiSE) 4th floor Room 4C-6, 3-25-13 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-0821, Japan.
6 Department of Advanced Informatics for Genetic Diseases, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
7 Department of Urology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. shorie@juntendo.ac.jp.
8 Department of Advanced Informatics for Genetic Diseases, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. shorie@juntendo.ac.jp.
9 Institute for Advanced Biosciences, Keio University, 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata, 997-0052, Japan. sfukuda@sfc.keio.ac.jp.
10 Transborder Medical Research Centre, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan. sfukuda@sfc.keio.ac.jp.
11 Systems Biology Programme, Graduate School of Media and Governance, Keio University, 5322 Endo, Fujisawa, Kanagawa, 252-0882, Japan. sfukuda@sfc.keio.ac.jp.
12 Kanagawa Institute of Industrial Science and Technology, Life Science & Environment Research Centre (LiSE) 4th floor Room 4C-6, 3-25-13 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-0821, Japan. sfukuda@sfc.keio.ac.jp.
PMID: 35418210 DOI: 10.1038/s41391-022-00536-3
Abstract
Background: It is estimated that by 2040 there will be 1,017,712 new cases of prostate cancer worldwide. Androgen deprivation therapy (ADT) is widely used as a treatment option for all disease stages. ADT, and the resulting decline in androgen levels, may indirectly affect gut microbiota. Factors affecting gut microbiota are wide-ranging; however, literature is scarce on the effects of ADT on gut microbiota and metabolome profiles in patients with prostate cancer.
Methods: To study the changes of gut microbiome by ADT, this 24-week observational study investigated the relationship between testosterone levels and changes in gut microbiota in Japanese patients with prostate cancer undergoing ADT. Sequential faecal samples were collected 1 and 2 weeks before ADT, and 1, 4, 12, and 24 weeks after ADT. Blood samples were collected at almost the same times. Bacterial 16 S rRNA gene-based microbiome analyses and capillary electrophoresis-time-of-flight mass spectrometry-based metabolome analyses were performed.
Results: In total, 23 patients completed the study. The α- and ß-diversity of gut microbiota decreased significantly at 24 weeks after ADT (p = 0.017, p < 0.001, respectively). Relative abundances of Proteobacteria, Gammaproteobacteria, Pseudomonadales, Pseudomonas, and concentrations of urea, lactate, butyrate, 2-hydroxyisobutyrate and S-adenosylmethionine changed significantly after ADT (p < 0.05). There was a significant positive correlation between the abundance of Proteobacteria, a known indicator of dysbiosis, and the concentration of lactate (R = 0.49, p < 0.01).
Conclusions: The decline in testosterone levels resulted in detrimental changes in gut microbiota. This dysbiosis may contribute to an increase in frailty and an increased risk of adverse outcomes in patients with prostate cancer.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.